Modified recombinant human erythropoietin with potentially reduced immunogenicity

Modified recombinant human erythropoietin with potentially reduced immunogenicity

Abstract Recombinant human erythropoietin (rHuEPO) is a biopharmaceutical drug given to patients who have a low hemoglobin related to chronic kidney disease, cancer or anemia. However, some patients repeatedly receiving rHuEPO develop anti-rHuEPO neutralizing antibodies leading to the development of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Thanutsorn Susantad, Mayuree Fuangthong, Kannan Tharakaraman, Phanthakarn Tit-oon, Mathuros Ruchirawat, Ram Sasisekharan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/18ae4af54d95460894f2257d68c11d8a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares